2020

Kuala Lumpur, December 18, 2019 – Duopharma Biotech Berhad (formerly known as CCM Duopharma Biotech Berhad) (“Duopharma Biotech”) today unveiled its new corporate logo and name at an external rebranding launch. The Company obtained shareholders’ approval for the new corporate identity earlier this year. Duopharma Biotech, which is majority owned by Permodalan Nasional Berhad (PNB), is the largest Malaysian pharmaceutical manufacturer and trading company.

KUALA LUMPUR, 12 NOVEMBER 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a solid set of financial results for the third quarter ended 30 September 2020 with profit before tax holding steady at RM18.57 million (2019: RM19.77 million) against revenue of RM133.77 million (2019: RM142.86 million) despite impact of Covid-19 pandemic.

Duopharma HAPI Sdn Bhd to embark on CML drug after successful production and commercialisation of breast cancer theraphy.

Duopharma Hapi Sdn Bhd to embark on CML drug after successful production and commercialisation of breast cancer therapy 

KUALA LUMPUR, 2 NOVEMBER 2020 – This year’s CHAMPS-NASOM Autism Awareness campaign in Malaysia has advanced to a new level as a result of wider industry collaboration, according to the National Autism Society of Malaysia (“NASOM”) and CHAMPS – Mothers’ Choice for Champions, the established child health supplement brand from the Consumer Healthcare (“CHC”) arm of leading pharmaceutical company Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”).

Shah Alam – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma
Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary,
Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its
first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam,
to help address the paucity of affordable alternatives to treat cancer.

Growing industry collaboration will reinforce CHAMPS-NASOM Autism Awareness Campaign into the future, says Duopharma Biotech Group MD
2020 CHAMPS-NASOM Autism Awareness Campaign, which marks the fourth year of Champs’ support of NASOM’s nation-wide drive to boost public awareness and acceptance of Autism, includes a contribution of RM50,000

Shah Alam, September 15, 2020 – Home-grown and rapidly evolving pharmaceutical industry player, Duopharma Biotech Berhad (“Duopharma Biotech” or the “Company”) through its wholly owned subsidiary, Duopharma HAPI Sdn Bhd will soon embark on manufacturing its second oncology drug at its first in Malaysia, Highly Potent Active Pharmaceutical Ingredient (HAPI) Plant in Shah Alam, to help address the paucity of affordable alternatives to treat cancer.

KUALA LUMPUR, 13 AUGUST 2020 – Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) has posted a creditable set of financial results for the second quarter ended 30 June 2020 with profit before tax climbing to RM19.39 million (2019: RM18.32 million) against revenue of RM143.33 million (2019: RM145.47 million).

Kuala Lumpur, 28th July 2020 – Around 500 top industry players gathered online to participate in a webinar held in conjunction with the World Halal Conference (WHC) 2020 webinar series spotlighting the halal pharmaceutical industry.The webinar, entitled ‘Embracing a Halal Pharmaceutical Eco-System’, was organised by the Halal Development Corporation (HDC) in collaboration with Duopharma Biotech Berhad (Duopharma Biotech), and KPJ Healthcare Berhad (KPJ) hosted by the Ministry of International Trade and Industry (MITI).